Literature DB >> 16201281

Preparation of arsenic trioxide albumin microspheres and its release characteristics in vitro.

Jie Zhou1, Fuqing Zeng, Gao Xiang, Shusheng Xie, Shuli Wei.   

Abstract

Arsenic trioxide albumin microspheres (As2O3-BSA-NS) were prepared by using methods of chemical cross-linking. The desirability function (DF), calculated according to the size (<1 microm) distribution, drug loading and drug trapping efficiency, was introduced as a total index for the microspheres formulation. Four factors, inculding W/O ratio, decentralization speed, BSA concentration and stirring stabilization time, were selected and arranged in an orthogonal experimental table. The release characteristic was studied by the drug release experiment in vitro. The four factors affected DF differently. Decentralization speed behaved as the maximum (P<0.01), followed by BSA concentration (P<0.05) and the W/O ratio dose (P<0.05). Stirring stabilization time did not influence DF (P>0.05). The release experiment in vitro showed that As2O3 in As2O3-BSA-NS was released more slower than pure As2O3. It was concluded that regular As2O3-BSA-NS may be prepared by the methods of chemical cross-linking, which was optimized by orthogonal experimental analysis of different factors, and the microspheres can release As2O3 slowly.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16201281     DOI: 10.1007/bf02828152

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  11 in total

1.  Optimization of the formulation design of chitosan microspheres containing cisplatin.

Authors:  Y M Wang; H Sato; I Adachi; I Horikoshi
Journal:  J Pharm Sci       Date:  1996-11       Impact factor: 3.534

2.  Arsenic trioxide-induced apoptosis through oxidative stress in cells of colon cancer cell lines.

Authors:  Yoshihito Nakagawa; Yukihiro Akao; Hiroshi Morikawa; Ichiro Hirata; Kenichi Katsu; Tomoki Naoe; Nobuko Ohishi; Kunio Yagi
Journal:  Life Sci       Date:  2002-03-29       Impact factor: 5.037

3.  Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients.

Authors:  C Niu; H Yan; T Yu; H P Sun; J X Liu; X S Li; W Wu; F Q Zhang; Y Chen; L Zhou; J M Li; X Y Zeng; R R Yang; M M Yuan; M Y Ren; F Y Gu; Q Cao; B W Gu; X Y Su; G Q Chen; S M Xiong; T D Zhang; S Waxman; Z Y Wang; Z Chen; J Hu; Z X Shen; S J Chen
Journal:  Blood       Date:  1999-11-15       Impact factor: 22.113

4.  Apoptosis inducing effects of arsenic trioxide on human bladder cancer cell line BIU-87.

Authors:  Q Tong; F Zeng; L Zheng; J Zhao; G Lu
Journal:  Chin Med J (Engl)       Date:  2001-04       Impact factor: 2.628

5.  Arsenic compounds induce cytotoxicity and apoptosis in cisplatin-sensitive and -resistant gynecological cancer cell lines.

Authors:  Y H Du; P C Ho
Journal:  Cancer Chemother Pharmacol       Date:  2001-06       Impact factor: 3.333

6.  Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer.

Authors:  H Maeda; S Hori; H Nishitoh; H Ichijo; O Ogawa; Y Kakehi; A Kakizuka
Journal:  Cancer Res       Date:  2001-07-15       Impact factor: 12.701

7.  Functional repression of estrogen receptor a by arsenic trioxide in human breast cancer cells.

Authors:  Gui-Cai Chen; Li-Shuang Guan; Wei-Lian Hu; Zhao-Yi Wang
Journal:  Anticancer Res       Date:  2002 Mar-Apr       Impact factor: 2.480

8.  Arsonoliposomes: effect of arsonolipid acyl chain length and vesicle composition on their toxicity towards cancer and normal cells in culture.

Authors:  Olga Gortzi; Sophia G Antimisiaris; Pavlos Klepetsanis; Evangelia Papadimitriou; Panayiotis V Ioannou
Journal:  Eur J Pharm Sci       Date:  2003-02       Impact factor: 4.384

9.  Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance.

Authors:  C Cuvier; L Roblot-Treupel; J M Millot; G Lizard; S Chevillard; M Manfait; P Couvreur; M F Poupon
Journal:  Biochem Pharmacol       Date:  1992-08-04       Impact factor: 5.858

10.  Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.

Authors:  S L Soignet; P Maslak; Z G Wang; S Jhanwar; E Calleja; L J Dardashti; D Corso; A DeBlasio; J Gabrilove; D A Scheinberg; P P Pandolfi; R P Warrell
Journal:  N Engl J Med       Date:  1998-11-05       Impact factor: 91.245

View more
  2 in total

1.  Recent advances in arsenic trioxide encapsulated nanoparticles as drug delivery agents to solid cancers.

Authors:  Anam Akhtar; Scarlet Xiaoyan Wang; Lucy Ghali; Celia Bell; Xuesong Wen
Journal:  J Biomed Res       Date:  2017-01-19

2.  Chemoembolizing hepatocellular carcinoma with microsphere cored with arsenic trioxide microcrystal.

Authors:  Degang Kong; Tao Jiang; Jian Liu; Xinyi Jiang; Bei Liu; Cheng Lou; Baobing Zhao; Steven L Carroll; Gong Feng
Journal:  Drug Deliv       Date:  2020-11-26       Impact factor: 6.419

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.